Usefulness of an implantable antitachycardia pacemaker system for supraventricular or ventricular tachycardia (original) (raw)
1986, The American Journal of Cardiology
AI-generated Abstract
The utility of the Cordis Omni-Orthocor@ implantable antitachycardia pacemaker system was evaluated in 13 patients with supraventricular tachycardia (SVT) or ventricular tachycardia (VT). It demonstrated successful termination of arrhythmias and facilitated noninvasive electrophysiological studies, enhancing patient safety and treatment acceptability. Long-term follow-up revealed variable tachycardia termination zones in patients on amiodarone and highlighted the device's capabilities for induced tachycardia termination and reliable electrophysiological testing.
Sign up to get access to over 50M papers
Related papers
Pacing and Clinical Electrophysiology, 1990
Intertach 262-12 tachycardia reversion pulse generafor was implanted in 14 patients (six male, eight female, mean age at impianlation 45 ± 16 years) with recurrent symptomatic tachycardias. Six patients had atrioventricuiar (AV) nodal reentrant tachycardia, three patients had orthodromic tachycardia with Wolff-Parkinson-White syndrome, two had circus movement tachycardia via a concealed bypass tract, two had ventricular tachycardia, one patient had atrial flutter. Mean duration of symptoms be/ore implantation was 8 ± 4 years and mean number of antiarrhythmic drug trials was 3.5 ± 1. The primary tachycardia response mode consisted of autodecremental pacing in one patient, burst pacing in two patients, and adaptive scanning of the initial delay or burst cycle length in eleven patients. The secondary tachycardia response mode consisted of autodecremental pacing in four patients, burst pacing in three patients and burst scanning in four patients. Tachycardia response was automatic in all but one patient with ventricular tachycardia. During a follow-up period of 30.5 ± 10.6 months, one patient with ventricular tachycardia died from a nonarrhythmic cause, fieinterventions were necessary due to electrode fracture in one patient and due to pacemaker software defect in another one. Two patients underwent surgical care of their arrhythmia: one patient with atrial flutter and one patient with AV nodai reentry tachycardia, 24 months and 11 months postpacemaker implantation, respectively. Four patients required digitalis to prevent pacing induced atriai _ftbriliation. Other proarrhythmic effects were not encountered. The pacemaker proved to be a versatile system with reliable tachycardia detection and termination functions. It provided a valuable adjunctive therapy in these selected patients. (PACE, Vol. 13, July }990} antitachycardia pacing, supraventricular tachycardia, ventricular tachycardia
Pacing and Clinical Electrophysiology, 1985
An Omni Orthocor 234A special device pacemaker was implanted in nine patients for treatment of drug-resistant supraventricular tachycardia (three patients) or ventricular tachycardia (six patients). This device is activated using a special external unit, which delivers from six to 15 stimuli at preselected coupling intervals ranging from 195 to 500 ms. Serial noninvasive electrophysiology studies were performed either in the hospital or on an outpatient basis using the triggered mode, which can respond to programmed chest wall stimulation. Three patients with reciprocating supraventricular tachycardia were treated effectively by this device during an average follow-up of 2.2 years. Of the six patients with stable ventricular tachycardia amenable to pacemaker termination, only four remained successful during an average follow-up of 1.9 years. Such devices may find important use in serial noninvasive electrophysiologic testing during long-term clinical follow-up. The present form of this device is inadequate for widespread application, but may be useful for highly selected individuals.
Management of Tachyarrhythmias with Dual-Chamber Pacemakers
Pace-pacing and Clinical Electrophysiology, 1983
Des stimulaleurs multiprogrammables AV séquentiels de type “double-demande” (DVI, MN) ont été implantés chez 23 patienls porteurs ?anomalies variées de tachycardies supraventriculaires. De plus, des stimuloteurs AV séquenfiels à paire “nonobligée” (DVI, MN e(DDD, M) ont été utilisés pour le traitement de lachyarhythmies ventriculaires. Nous avons observé que ľexpérience avec ee type de stimulateur multiprogrammable est favorable chez les patients sans fibrillation auriculaire chronique, qui ont besoin ?un stimutafeur et qui nécéssitent un froilement anti-tachycardique. Ľévolution des stimulateurs du type DDD contribuera sans doute à un traitement encore plus éfficace.Multi-programmable dual-demand AV sequential (DVI, MN) pacemakers were implanted in twenty-three potients (in one of them a DVI, MN unit was used as a VVI, MN with the aid of an atrial plug) with suproventricular tachycardias after electrophysiological studies revealed a great voriety of AV reentry circuits. The latter included tachycardios involving accessory pathways of the Kent type, manifest or concealed Wolff-Parkinson-White syndromes, nodo-ventricular (Mahaim) tracts, “enhanced” AV node for extra AV nodal) pothwaysand dual AV pathways. In addition, multiprogrammable “non-committed” AV sequential (DVI, MN and DDD, M) pacemakers were permanently implonted to treat different forms of ventricular tachyarrhythmias that included: torsode de pointes in the Romano-Ward syndrome and Chagas' cardiomyopathy, ventricular tachycordia which is bradycardia-dependent (in Chagas' cardiomyopathy) and reciprocal beats indueed by, and producing severe hemodynamic derangements in a patient with a conventional VVI unit. With smallsize multiprogrammable units, arrhythmias may be treated by changing parameters non-invasively. By temporary inhibition, one may analyze the underlying rhythm and pacemaker dependency. In potients without chronic atrial flutterJfibrillation who require pacing and possibly tachyarrhythmia control, our experience with multiprogrammable “non-committed” AV sequential pacing has been very satisfactory. The evolution toward newer pacing modes which provide atrial sensing and trackmg (DDD), and thus preserve AV synchrony over a wider range of atrial rates, may contribute even further to successful patient management. This may be applicable to pediatric patients as well.
Loading Preview
Sorry, preview is currently unavailable. You can download the paper by clicking the button above.